Investigating Emotional Intelligence: A Cross-Sectional Study of Pune's Postgraduate Medical Scholars.

Introduction Emotional intelligence (EI), which encompasses the ability to perceive, understand, and manage emotions, is crucial for effective human interaction. In healthcare, especially in medicine, compassion and empathy are prioritized qualities associated with enhanced patient outcomes, increased patient compliance, and overall improved healthcare experiences. This study focused on postgraduate medical students to assess their EI levels and identify influencing factors.

In-silico and In-vitro Evaluation of Novel Carboxamide Analogue on the Metastasis of Triple Negative Breast Cancer Cells Utilizing Novel PCPTC-loaded PEGylated-PLGA Nanocarriers.

This study aimed to determine the effects of novel N-{3-[(pyridin-4-yl)carbamoyl] phenyl} thiophene-2-carboxamide or PCPTC chemical moiety loaded Poly(lactic-co-glycolic acid)-Poly (Ethylene glycol) or (PLGA-PEGylated) NP as an anti-metastatic Ran GTPase therapeutic agent on MDA-MB231 triple-negative human breast cancer cells. Molecular docking and MD simulation was done to determine the binding potential of novel carboxamide PCPTC with Ran GTPase. PLGA and PLGA-PEG based NP encapsulating PCPTC were fabricated using the Modified Double Emulsion Solvent Evaporation Technique and characterized for size, zeta potential, polydispersity and morphology.

Clinical outcomes of abbreviated high dose-rate brachytherapy in locally advanced cervical cancer: lessons from the COVID pandemic for high dose-rate fractionation.

Purpose: To evaluate outcomes of cervical cancer patients treated with abbreviated high dose rate brachytherapy (HDR-BT) that used 2-implants and delivered 4-5 fractions over 7-12 days rather than 21-28 days.

Materials And Methods: Patients with stage IB2-IVA cervical cancer, treated with external beam radiation (EBRT) ± chemotherapy followed by abbreviated MR/CT-based HDR-BT were included. The planning aim was to achieve > 70Gy equivalent doses in 2Gy (EQD2) at Point A dose in patients undergoing intracavitary BT (ICBT) and > 85Gy EQD2 to the HRCTV in intracavitary-interstitial BT (IC-ISBT).